

Influenza Workgroup

Introduction

Ruth Karron, MD

Advisory Committee on Immunization Practices

June 25, 2014

Influenza Work Group

ACIP Members

Ruth Karron (Chair)
Jeff Duchin (Outgoing)
Lee Harrison

***Ex Officio* Members**

Melisse Baylor (FDA)
David Cho (FDA)
Jesse Geibe (DoD)
Bruce Gellin (HHS)
Lucia Lee (FDA)
Cynthia Noletti (FDA)
Rachelle Salomon (NIH)

CDC Lead

Lisa Grohskopf (CDC/OID/NCIRD,
Influenza Division)

Liaison Representatives

Kevin Ault (ACOG)
Hank Bernstein (AAP)
Jan Englund (PIDS)
Sandra Fryhofer (ACP; AMA)
Marie-Michèle Léger (AAPA)
Susan Lett (CSTE)
Jamie Loehr (AAFP)
Kathy Neuzil (IDSA)
Lisa Ipp (SAHM)
William Schaffner (NFID)
Rob Schechter (AIM)
Ken Schmader (AGS)
Nadine Sicard (NACI)
Patsy Stinchfield (NAPNAP)
Tamara Sheffield (AHIP)
Matthew Zahn (NACCHO)

Consultant

Wendy Keitel

WG Discussion Since February 2014

- ❑ Relative efficacy and safety of LAIV and IIV for children**
 - Further discussion of language and considerations for use of LAIV and IIV when both are available
 - Review of data on use of LAIV or IIV in children with a history of asthma or wheezing and other high risk conditions

- ❑ Discussion of dose algorithm for children aged 6 months through 8 years**

- ❑ Finalized draft 2014-15 ACIP Influenza Statement**

Agenda Overview

- ❑ **Novel Influenza Vaccine Work Group Update**
 - Dr. Douglas Campos-Outcalt (ACIP)

- ❑ **Influenza Vaccine Safety Update**
 - Maria Cano (CDC—Immunization Safety Office)

- ❑ **Assessing Fever Rates in Children Following LAIV and IIV**
 - Melissa Stockwell (Columbia University)

- ❑ **LAIV and IIV for children ages 2 through 8 years**
 - Lisa Grohskopf (CDC—Influenza Division)

- ❑ **Proposed Recommendations**
 - Lisa Grohskopf (CDC—Influenza Division)